Veru Inc.
$2.43
▲
0.88%
2026-04-21 10:06:01
verupharma.com
NCM: VERU
Explore Veru Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$39 M
Current Price
$2.43
52W High / Low
$7.4 / $2.06
Stock P/E
—
Book Value
$2.31
Dividend Yield
—
ROCE
-161.13%
ROE
-60.25%
Face Value
—
EPS
$-1.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
-1.34
Debt / Equity
8.02
Current Ratio
5.16
Quick Ratio
2.43
Forward P/E
-1.98
Price / Sales
—
Enterprise Value
$5.88 M
EV / EBITDA
-0.2
EV / Revenue
—
Rating
None
Target Price
$25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 2. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 3. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 4. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 5. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 6. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 7. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.42 M | -7.46 M | -8.03 M | -9.1 M | -10.94 M | — |
| Net Profit | -5.33 M | 1.45 M | -7.33 M | -7.9 M | -8.95 M | — |
| EPS in Rs | -0.33 | 0.09 | -0.46 | -0.49 | -0.56 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 16.3 M | 39.35 M |
| Operating Profit | -35.53 M | -37.39 M | -95.61 M | -83.49 M |
| Net Profit | -22.73 M | -37.8 M | -93.15 M | -84.04 M |
| EPS in Rs | -1.42 | -2.36 | -5.8 | -5.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 29.84 M | 60.42 M | 50.02 M | 135.36 M |
| Total Liabilities | 11.5 M | 28.1 M | 30.34 M | 52.56 M |
| Equity | 18.33 M | 32.32 M | 19.68 M | 82.8 M |
| Current Assets | 18.92 M | 35.22 M | 22.93 M | 104 M |
| Current Liabilities | 7.79 M | 11.87 M | 17.81 M | 38.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -30.04 M | -21.68 M | -88.01 M | -47.51 M |
| Investing CF | 25.14 M | 0.15 M | 6.33 M | 4.27 M |
| Financing CF | -4.22 M | 36.83 M | 11.11 M | 1.07 M |
| Free CF | -30.04 M | -21.84 M | -88.68 M | -48.24 M |
| Capex | -0 M | -0.16 M | -0.67 M | -0.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -58.59% | — | — |
| Earnings Growth % | 59.42% | -10.84% | — | — |
| Profit Margin % | — | -571.6% | -213.55% | — |
| Operating Margin % | — | -586.65% | -212.14% | — |
| Gross Margin % | — | 46.43% | 77.73% | — |
| EBITDA Margin % | — | -552.1% | -201.31% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-11 | 1:0.1 |